Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK7 | P50613 | 1/20 | 0.44 |
| ▸ | CCNH | P51946 | 1/20 | 0.44 |
| ▸ | MNAT1 | P51948 | 1/20 | 0.44 |
| ▸ | ANO1 | Q5XXA6 | 1/20 | 0.43 |
| ▸ | CCNA2 | P20248 | 3/20 | 0.41 |
| ▸ | CDK2 | P24941 | 3/20 | 0.41 |
| ▸ | CCNA1 | P78396 | 3/20 | 0.41 |
| ▸ | NPC1 | O15118 | 5/20 | 0.40 |
| ▸ | RAB9A | P51151 | 5/20 | 0.40 |
| ▸ | ATM | Q13315 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.38 |
| ▸ | CTBP2 | P56545 | 1/20 | 0.37 |
| ▸ | CACNA1G | O43497 | 1/20 | 0.36 |
| ▸ | CACNA1H | O95180 | 1/20 | 0.36 |
| ▸ | CACNA1I | Q9P0X4 | 1/20 | 0.36 |
| ▸ | PSEN1 | P49768 | 1/20 | 0.36 |
| ▸ | PSEN2 | P49810 | 1/20 | 0.36 |
| ▸ | APH1B | Q8WW43 | 1/20 | 0.36 |
| ▸ | NCSTN | Q92542 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18556898 | 0.88 | RAB9A (0.49) | CDK7CCNHMNAT1CCNA2CDK2 | |
| SCHEMBL16675928 | 0.84 | NPC1 (0.39) | CDK7CCNHMNAT1ANO1CCNA2 | |
| SCHEMBL16675926 | 0.79 | CCNA2 (0.41) | CCNA2CDK2CCNA1NPC1RAB9A | |
| SCHEMBL16675921 | 0.78 | CCNA2 (0.40) | CCNA2CDK2CCNA1NPC1RAB9A | |
| SCHEMBL16675907 | 0.77 | CDK2 (0.46) | CDK7CCNHMNAT1CCNA2CDK2 | |
| SCHEMBL16682132 | 0.76 | CCNA2 (0.46) | CCNA2CDK2CCNA1CTBP2 | |
| SCHEMBL16675912 | 0.75 | RET (0.39) | CDK7CCNHMNAT1ANO1CCNA2 | |
| SCHEMBL16675923 | 0.74 | RET (0.38) | CCNA2CDK2CCNA1NPC1RAB9A | |
| SCHEMBL16675931 | 0.74 | CDK2 (0.37) | CCNA2CDK2CCNA1NPC1RAB9A | |
| SCHEMBL16682182 | 0.73 | CACNA1H (0.41) | ANO1CDK2CACNA1GCACNA1HCACNA1I |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9580391-B2 | Saturated acyl guanidine for inhibition of F1F0-ATPase | LYCERA CORPORATION (US) | 2017-02-28 | — | — | US | disclosed |
| US-20150119439-A1 | SATURATED ACYL GUANIDINE FOR INHIBITION OF F1F0-ATPASE | WILMINGTON TRUST, NATIONAL ASSOCIATION | 2015-04-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150119439-A1 | SATURATED ACYL GUANIDINE FOR INHIBITION OF F1F0-ATPASE | ATP5F1A, ATP5F1D, ATP5F1C | CDK7 3027/4885CCNH 2940/4885MNAT1 1843/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.